| CHMP in Favor of Pfizer's Axitinib - Zacks.com |
|
|
Zacks.com Pfizer (PFE - Analyst Report) recently announced that its renal cell cancer candidate, axitinib, received a positive opinion from the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA). Pfizer is seeking EU approval ... Pfizer's Axitinib gets positive opinion from CHMP for second-line treatment of |